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ABSTRACT 
 
Hypoxic stress is a consequence of the decrease in the oxygen reaching the 
tissues of the body. The coupling of energy with oxygen makes low tension oxygen 
sensing and adaptation very essential for survival. The intracellular partial pressure of 
oxygen is regularly measured by a family of hydroxylase enzymes named as prolyl 
hydroxylase domain containing proteins (PHD). Hypoxia Inducible Factor (HIF) is the 
transcription factor that controls the ability of the cell to balance between adaptation and 
cell death during hypoxia.  
During normoxia, HIF1α undergoes non-reversible hydroxylation in the presence 
of PHD2. The hydroxylated HIF1α interacts with von Hippel-Lindua tumor suppressor 
protein (pVHL) and is degraded by ubiquitination. During hypoxia, PHD2 is inhibited 
which results in HIF-1α stabilization. Stabilized HIF-1α enters the nucleus and 
heterodimerizes with Hypoxia Inducible Factor-1β and the dimeric transcription factor 
HIF-1 is formed which binds to the response elements of the target genes. HIF-regulated 
target genes enable cells to induce an adaptive response by increasing glycolysis; 
angiogenesis etc. or undergo cell death by promoting apoptosis or necrosis.  
In this work, a Boolean network is generated whose state transitions realize the 
hypoxic stress response pathway. The simulated behavior of the Boolean network 
obtained is consistent with the experimental results from the already published pathway 
literatures.  
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NOMENCLATURE 
 
HIF Hypoxia Inducible Factor 
VHL Von Hippel Lindau tumor suppressor protein 
VEGF Vascular Endothelial Growth Factor 
ETC Electron Transport Chain 
HRE Hypoxia Response Element 
PHD Prolyl Hydroxylase Domain containing proteins 
ARNT Aryl Hydrocarbon Nuclear Trans locator 
mRNA messenger Ribo Nucleic Acid 
NADH Nicotine Amide Dinucleotide (reduced form) 
FAD Flavin Adenine Dinucleotide 
GAPDH Glyceraldehyde Phosphate Dehydrogenase 
LDHA Lactate Dehydrogenase A 
PDH Pyruvate Dehydrogenase 
PDK Pyruvate Dehydrogenase Kinase 
ETC Electron Transport Chain 
ATP Adenosine Tri Phosphate 
ADP Adenosine Di Phosphate 
NAD+ Nicotine Amide Dinucleotide 
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1. INTRODUCTION 
 
1.1 Introduction 
Hypoxia is a condition in which there is an inadequate supply of oxygen to the 
tissues of the body. If the oxygen entering inside a cell is not matching the oxygen 
demand of the same cell, a hypoxic condition is created. [1] Hypoxic stress is caused 
when the amount of oxygen available in a cell is insufficient to meet the energy demands 
of that cell. In a living cell, this imbalance between oxygen supply and energy demand 
arises due to physiological and pathophysiological processes. [2]. A cell faces hypoxic 
stress due to normal physiological variations during fetal development, wound healing, 
adapting to a high altitude, inflammation etc. [2] In a developing embryo, hypoxic stress 
is due to reduced oxygen supply, whereas while doing vigorous exercise, a hypoxic 
condition is created in the exercising muscles due to an increased demand of energy. [3] 
The optimum oxygen tension for tubulogenesis, vasculogenesis and angiogenesis in an 
embryo of a mammal is about 23-38 mm Hg. [2]  
1.2 Partial pressure of oxygen and hypoxia 
Different cells in the body have different partial pressures of oxygen that are 
considered to be normal and dropping of the partial pressure of oxygen these normal 
levels, create a hypoxic condition.  The difference of the partial pressures of oxygen 
between the blood and the mitochondria of the cells is responsible for the transfer of 
oxygen between blood and all the cells in the body. [2] Hypoxia detection in human 
beings is carried out by the most vascular tissue in the human body, the carotid body, 
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which is located near the bifurcation of the carotid artery. [4] The partial pressures of 
inhaled air, arterial blood and venous blood are 150 mm Hg, 100 mm Hg and 40 mm Hg 
respectively. [2] The carotid body detects the gradient of the partial pressure of oxygen 
of the arterial blood that flows through the carotid body. [5] The intracellular PO2 is 
regularly measured by three hydroxylases. These hydroxylases are named as prolyl 
hydroxylase domain containing proteins (PHD), namely PHD1, PHD2, and PHD3. [2] 
1.3 Metabolic reactions and hypoxia 
Almost 95% of the oxygen that we breathe in is used up by the reactions of the 
Electron Transport Chain (ETC), catalyzed by cytochrome oxidase, to produce energy. 
[2] A gradient of protons is created across the innermost membrane of mitochondria as a 
result of some redox reactions taking place in the mitochondrial ETC, due to the transfer 
of electrons from an electron donor to the terminal electron acceptor, oxygen. This 
proton gradient is used to phosphorylate ADP to form ATP in the presence of ATP 
synthase.  The inhaled air, which has a partial pressure of 150 mm Hg, passes into the 
alveoli which are the small air sacs located inside the lungs. Oxygen mixes with the 
water vapor and carbon dioxide (external respiration) and then enters into the arterial 
blood with a partial pressure of 13.3 KPa.  Arterial blood carries oxygen to the 
mitochondria in each and every cell of the body, where it extracts hydrogen from the 
food to react with oxygen to produce water vapor. Carbon dioxide produced in the 
mitochondria enters into the venous blood and is expelled from the lungs. The normal 
partial pressure of oxygen in the arterial blood is 100 mm Hg, and when it falls to 40 mm 
Hg, it is very dangerous. [6] Hence, low oxygen tension should be identified and proper 
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adaptation measures should be taken by the cell for survival, because oxygen 
consumption is coupled to release of energy in the form of ATP, which is essential for 
the proper functioning of the cell.   
1.4 Hypoxia and cancer 
Hypoxia can also occur due to pathophysiological processes, especially cancer.  
Hypoxia is a prominent condition observed in solid tumors, stroke, atherosclerosis, 
asthma, chronic bronchitis, emphysema, neuronal cell death and disability.  Myocardial 
hypoxia, cerebral hypoxia, alveolar hypoxia etc. are very detrimental to the human body. 
[2] Hypoxia is a very prominent character displayed by almost all solid tumors, since 
rapid cell growth demands a lot of energy, and hence oxygen becomes a limiting factor. 
As the tumor grows to about 2-3mm in diameter, the normal oxygen supply falls short to 
satisfy the increase in energy requirement of cancer tissues. The cells adapt to this 
scarcity by creating new blood vessels from the already existing blood vessels 
(angiogenesis) and also by increasing the glycolytic rate for easy and faster energy 
production. [7]  
1.5 Adaptation to hypoxic stress 
To maintain the proper tissue function, an adaptive response must be 
incorporated to overcome the scarcity of oxygen in order to harvest energy from food. 
The transcription factor HIF (Hypoxia Inducible Factor) has a prominent role in the gene 
expression regulation by oxygen. HIF achieves this response by regulating the 
transcription of thousands of hypoxia responsive genes. The interaction of HIF was 
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identified for the first time in erythropoietin (EPO) gene which is involved in 
angiogenesis. [2] EPO gene was up regulated almost 100 fold by hypoxia. [8] 
1.6 Hypoxia Inducible Factor (HIF) and its regulation 
Hypoxia Inducible Factor (HIF) is a heterodimer comprising of α and β subunits.  
HIFα consists of 3 subunits, HIF1α, HIF2α and HIF3α.The HIFβ subunit consists of 
ARNT which is the aryl hydrocarbon nuclear translocator and ARNT2. HIF1 
transcription factor consists of HIF1α and HIF1β (ARNT). [9] The concentration of 
oxygen in the cells regulate the HIF1α subunit, but the HIF1β subunit is unaffected by 
the concentration of oxygen. HIF1α quickly stabilizes and is accumulated on hypoxic 
conditions by the inhibition of PHD2, but on re oxygenation, it is suddenly destroyed 
and its half-life is less than 5 minutes. [10] This short half –life shows that HIF1α 
accumulation is not good for the body. In fact, prolonged hypoxia is observed in most of 
the tumors.   
HIF1 α undergoes hydroxylation of the amino acid proline located in its oxygen 
dependent degradation (ODD) domain by PHD2. [2]   HIF1 α undergoes hydroxylation 
of the asparagine 803 residues located in the C terminal activation domain (CTAD) by 
FIH (factor inhibiting HIF). [11] The hydroxylation of HIF1α by PHD2 increases its 
interaction with the tumor suppressor protein, pVHL, the von-Hippel Lindau tumor 
suppressor protein which marks HIF1α for degradation with the help of E3 ubiquitin –
ligase. [2] PHD2 hydroxylates HIF1α and that create a binding site for pVHL [12] 
Again, the hydroxylation of HIF1α by FIH reduces the transcriptional activity of HIF1α 
by preventing the binding of coactivators p300/CBP to HIF1α. [13] The hydroxylation 
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of HIF1α by FIH results in p300/CBP independent transcription of HIF1α.  PHD and 
FIH require oxygen, iron, α Keto Glutarate (αKG) and ascorbate as substrates to function 
properly. Oxygen and αKG are the co-substrates required for PHD2 functioning 
whereas, ascorbate and Fe2+ (iron) are the cofactors required for PHD2 functioning. 
PHD2 hydroxylates HIF1α and simultaneously PHD2 decarboxylates αKG to succinate. 
[2] αKG is an anion of α keto- glutaric acid which is produced by the deamination of 
glutamate, an intermediate of the citric acid cycle. [14] During hypoxia, the substrate 
oxygen required for PHD functioning is not available and hence PHD is inhibited. This 
results in the activation and stabilization of HIFα subunit which enters into the nucleus 
and binds with HIFβ subunit to form HIF heterodimer. [12], [13] HIF transcription factor 
binds to the Hypoxia Responsive Elements (HRE) of the target genes and this interaction 
drives the transcription in a hypoxia responsive manner up regulating the genes involved 
in angiogenesis (EPO), vasculogenesis (VEGF), glycolysis (GLUT1, PDK1, LDHA) etc.  
Electron Transport Chain (ETC) directs the electron transport between the electron 
donors NADH (Nicotinamide Adenine Dinucleotide) and FADH2 (Flavin Adenine 
Dinucleotide) to the terminal electron acceptor oxygen. ETC takes place inside the 
mitochondria where O2 is reduced to H2O, NADH is oxidized to NAD+ and succinate in 
the presence of Succinate Dehydrogenase (SDH) enzyme is converted to fumarate. [15] 
The gradient of proton generated across the membrane of mitochondria, pumps protons 
inside the mitochondrial space which converts Adenosine Di Phosphate to Adenosine Tri 
Phosphate with the enzyme ATP synthase. This whole process is what is termed as 
oxidative phosphorylation. [16] Some of the electrons will not be transferred from the 
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electron donor through the complexes I-IV to the terminal electron acceptor, but there 
may be premature electron leakage through complexes I and III forming reactive oxygen 
species (ROS) such as superoxide that creates oxidative stress. [17] During hypoxia ETC 
is inhibited since, there is not enough oxygen available, which generates more ROS 
creating an oxidative stress. [18] This oxidative stress does not allow iron to cycle 
between the oxidation states which results in PHD inhibition since, iron is one of the 
cofactors required for PHD to function properly. PHD inhibition results in the 
accumulation and stabilization of HIF1α which results in the induction of anti-apoptotic 
as well as apoptotic genes depending on the extent of hypoxia. [19] 
1.7 Switch from aerobic metabolism to anaerobic metabolism 
Activation of the transcription factor HIF1 results in a shift from aerobic 
metabolism to anaerobic metabolism.  Pyruvate kinase is an enzyme that converts 
Phospho Enol Pyruvate (PEP) to pyruvate. Pyruvate Kinase Muscle Isozyme 2(PK-M2) 
is one of the isozymes of the glycolytic enzyme Pyruvate Kinase [20]. PHD3 hydrolyzes 
PK-M2 on proline-403/408, and the hydrolyzed PK-M2 interacts directly with HIF1α 
subunit which enhances the binding of HIF1 to the HRE of the target genes. But, PKM2 
itself is a hypoxia target gene since, a hypoxia responsive element (HRE) was observed 
in the intron 1 of PK-M2. [21] PK-M2 promotes the Warburg effect. [22], [23] PK-M2 is 
identified in almost all the cancer cells and is essential for rapidly dividing cells since 
quicker energy harvesting is possible by shifting from aerobic to anaerobic metabolism. 
[24] Pyruvate Dehydrogenase Kinase 1(PDK1) is a HIF1 target gene.  PDK1, which is a 
hypoxia target gene, inhibits the action of the enzyme PDH, (Pyruvate Dehydrogenase) 
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which converts pyruvate to acetyl-co enzyme A. Hence, pyruvate is unable to enter into 
the citric acid cycle and is trapped in the cytosol and the rate of glycolysis is increased.  
This explains the Warburg effect and the relation between prolonged glycolysis and 
HIF1 activation.  
So, in effect PK-M2 catalyzes the conversion of PEP to pyruvate and PHD3 
hydrolyzes PK-M2 and the hydrolyzed PK-M2 enters the nucleus and interacts with 
HIF1α subunit and enhances the binding of HIF1 to the hypoxia responsive elements of 
the target genes. But, PK-M2 and PHD3 are hypoxia target genes. Moreover, PDK does 
not allow pyruvate to enter into citric acid cycle and traps pyruvate in the cytosol. 
Pyruvate inhibits PHD which stabilizes HIF1α, but PDK1 itself is a HIF target gene. 
Most of the glycolytic enzymes like GLUT1, LDHA, ALDA etc. are the hypoxia target 
genes and this explains the feed forward mechanism for HIF 1α activation and increased 
rate of glycolysis.  
1.8 Feedback inhibition 
PHD2 hydrolyzes HIF1α and the hydrolyzed HIF1α is degraded by the VHL 
tumor suppressor protein. But, PHD2 itself is a hypoxia target gene. [25], [26], [27] This 
feed-back inhibition acts a regulative control for hypoxic response when normoxia is re-
established. [2] Thus, HIF1:PHD2 linked transcription sets up the appropriate HIF1 
signaling to face the hypoxic stress effectively. [2]  
1.9 Hypoxic response based on the extent of hypoxia 
Hypoxic response can be either adaptive or apoptotic depending on the level of 
hypoxia. During normoxia, both catalytic enzymes PHD and FIH are active, which 
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results in the hydroxylation of proline and asparagine residues of HIF1α, resulting in the 
complete degradation of HIF1α by interacting with VHL.  During moderate hypoxia, 
PHD is inactive, whereas FIH is active since FIH requires only less oxygen 
concentration than PHD to function properly. [28] Here the transcription of HIF1 is 
limited, it occurs in a p300 independent manner. P300 is a coactivator which helps in 
rapid transcription.  In this condition, the cell tries to adapt to the hypoxic stress by up 
regulating the anti-apoptotic genes involved in angiogenesis (EPO), vasculogenesis 
(VEGF) and glycolysis (GLUT1, LDHA, ALDA etc.).  During, severe hypoxia, both the 
catalytic enzymes PHD and FIH are inactive and thus, there is a strong HIF1 
transcription resulting in a full- blown apoptotic response by up regulating the apoptotic 
genes p53, BNIP3, NIX etc. [25], [29], [30] There is an increased level of pro-apoptotic 
and apoptotic factors and p53 facilitated cellular injury in such a situation. Inhibiting the 
adaptive response could decrease the chance of survival of a cell when faced by hypoxic 
stress. [2]  
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2. METABOLIC SWITCH AND HYPOXIA 
 
2.1 Introduction 
Activation of the transcription factor HIF1 results in a switch from oxidative 
metabolism to glycolytic metabolism.  Hypoxia prevents the switch from glycolysis to 
citric acid cycle and glycolysis continues indefinitely so that the increasing energy 
demand during hypoxia can be met rapidly. The analysis of the mRNA of the HIF-1α 
deficient cells indicated that most of the enzymes involved in glycolysis is regulated by 
HIF-1 [2].  
2.2 Glycolysis 
Glycolysis is the central pathway of the glucose catabolism. It is a process by 
which glucose, which is a 6 carbon compound, is degraded to yield 2 molecules of 
pyruvate, which is a 3 carbon compound, in a sequence of ten enzyme catalyzed 
reactions. [15] The end product of glycolysis stores a lot of free energy and releases only 
a small fraction of the overall energy available inside the glucose molecule. The free 
energy released during glycolysis is preserved as ATP (Adenosine Tri Phosphate). The 
remaining free energy can be released only when the glycolytic products are completely 
oxidized into carbon dioxide and water with oxygen being the terminal electron 
acceptor. Glycolysis takes place in the cytoplasm and ten intermediate compounds are 
formed as a result of ten intermediate reactions catalyzed by glycolytic enzymes.   
There are two phases of glycolysis, the preparatory phase during which the ATP 
is consumed and the payoff phase during which ATP is generated.  There are total ten 
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reactions in glycolysis, out of which the first five are preparatory phase and the last five 
are payoff phase. In the preparatory phase, phosphorylation of glucose by ATP occurs in 
the presence of enzymes and finally 2 molecules of glyceraldehyde 3-phosphate is 
formed.  During the pay-off phase of glycolysis, NAD+ oxidizes glyceraldehyde 3-
phosphate with the help of glyceraldehyde phosphate dehydrogenase enzyme forming 1, 
3-diphosphoglycerate and simultaneously NAD+ is reduced to NADH. [15] The 1, 3-
diphosphoglycerate releases its phosphate group rich in energy to ADP to generate ATP 
and forms 3-phosphoglycerate. [15] This is the first ATP forming reaction. It then 
isomerizes into 2-phosphoglycerate in the presence of phosphor glycerate mutase 
enzyme and the latter undergoes dehydration with the help of enolase and forms 
Phospho Enol Pyruvate (PEP). [15] Then PEP releases its phosphate group rich in 
energy to ADP to form ATP in the presence of Pyruvate Kinase and pyruvate is formed 
simultaneously. [15] The reaction involving Pyruvate Kinase enzyme is the second point 
of regulation for glycolysis.  
Thus, two molecules are used in the preparatory phase whereas; four molecules 
of ATP are formed in the pay-off phase, resulting in a net yield of two ATP molecules 
for every glucose molecule undergoing glycolysis. During conversion of 
glyceraldehyde- 3-phosphate to 1, 3-diphosphoglycerate in the presence of the enzyme 
glyceraldehyde phosphate dehydrogenase (GAPDH), NAD+ is reduced to NADH. This 
NADH is transferred from cytosol to mitochondria by GAPDH which is activated by 
calcium ions (Ca2+). NAD is the product of cytosolic GAPDH activity. The pictorial 
representation of glycolysis is shown in figure 1. 
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Figure 1: Anaerobic glycolysis 
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2.3 Hypoxia and glycolysis 
Hypoxia and glycolysis is very much related since almost all the glycolytic 
enzymes are up regulated during hypoxia.  The analysis of m-RNA expression of HIF-1α 
deficient cells showed that the enzymes hexokinase (HK), glucose phosphate isomerase 
(GPI), phospho fructo kinase (PFK), aldolase, (TPI) triose phosphate isomerase, 
(GAPDH) glyceraldehyde phosphate dehydrogenase, (PGK) phospho glycerate kinase, 
phospho gluco mutase (PGM), enolase, (PK) pyruvate kinase and lactate dehydrogenase 
A (LDHA) are regulated by HIF-1. [31] Thus, the rate of glycolysis increases when cells 
undergo hypoxic stress. The end product of glycolysis, pyruvate inhibits PHD2 which 
results in the activation of HIF-1α and it enters into the nucleus and binds with HIF-1β to 
form the transcription factor HIF-1. Hypoxia Inducible Factor-1 which binds to the HRE 
of the hypoxia target genes which include almost all the glycolytic enzymes, thus 
increasing the rate of glycolysis. Moreover, Pyruvate dehydrogenase Kinase (PDK) is a 
hypoxia target gene which inhibits pyruvate dehydrogenase (PDH). PDH is the enzyme 
that converts pyruvate to Acetyl- coenzyme A. Hence, hypoxia inhibits the formation of 
acetyl coenzyme A and thereby prevents pyruvate from entering into the citric acid cycle 
and glycolysis continues indefinitely.   
Pyruvate kinase is the glycolytic enzyme that converts Phospho Enol Pyruvate 
(PEP) to pyruvate. Pyruvate Kinase Muscle Isozyme 2(PK-M2) is one of the isozymes 
of the glycolytic enzyme Pyruvate Kinase. [21] PHD3 hydrolyzes PK-M2 on proline-
403/408, and the hydrolyzed PK-M2 interacts directly with HIF1α subunit which 
enhances the binding HIF1 to the HRE of the target genes. But, PKM2 itself is a hypoxia 
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target gene since, a hypoxia responsive element (HRE) was observed in the intron 1 of 
PK-M2. PK-M2 promotes Warburg effect.  Warburg effect postulates that cancer cells 
produces a lot of energy rapidly by an increased rate of glycolysis which is followed by 
lactic acid fermentation rather than the decreased rate of glycolysis subsequently 
followed by oxidizing pyruvate inside the mitochondria by citric acid cycle and 
oxidative phosphorylation. [32] PK-M2 is identified in almost all the cancer cells and is 
essential for rapidly dividing cells since quicker energy harvesting is possible by 
switching from oxidative to glycolytic metabolism. 
  If glycolysis continues indeterminately, all NAD+ will be used up and glycolysis 
would come to a stop.  So, NADH must be oxidized back to NAD+ for the glycolysis to 
continue. There are three different mechanisms by which NADH can be oxidized back to 
NAD+. They are listed below. 
2.4 Lactic acid fermentation 
Pyruvate is reduced to lactate by Lactate Dehydrogenase A (LDHA) enzyme 
anaerobically. During this reaction, NADH is oxidized back to NAD+. This process is an 
important source of ATP during hypoxic conditions, for instance in infarcted heart 
muscle cells and while doing strenuous exercise. In many tissues, anaerobic lactic acid 
fermentation is a cellular last option for energy. The lactic acid fermentation by lactic 
acid bacteria causes milk to curdle (souring of milk) while making yogurt. [33] 
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2.5 Alcoholic fermentation 
Fermentation is defined as the anaerobic degradation of glucose into various 
products which are different for different organisms, solely for obtaining energy in the 
form of ATP [15].  The pyruvate formed from glucose is converted to ethanol and 
carbon dioxide, simultaneously oxidizing NADH to NAD+. 
2.6 Aerobic respiration 
In aerobic organisms, glucose is completely oxidized to CO2 as well as water and 
glycolysis is only the first stage of this aerobic oxidation. Then, pyruvate is 
decarboxylated in the presence of Pyruvate Dehydrogenase (PDH) enzyme to form the 
acetyl group of Acetyl-coenzyme A. This acetyl-coenzyme A then enters into the citric 
acid cycle where it is oxidized into CO2 and water and reduces NAD
+ to NADH.   
This reduced NADH is oxidized back to NAD+ by passing through the Electron 
Transport Chain (ETC). The electron is transferred through the Electron Transport Chain 
to oxygen and is finally reduced to water.  
This generates a proton gradient which is used to produce 2.5 moles of ATP for 
every NADH oxidized which is termed as Oxidative Phosphorylation. The three 
different mechanisms by which NADH is oxidized back to NAD+ is illustrated in figure 
2. 
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Figure 2: Mechanisms by which NADH is oxidized to NAD+ 
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2.7 Citric acid cycle 
Citric Acid Cycle or Tri Carboxylic Acid cycle (TCA cycle) or Krebs cycle is the 
final common pathway by which almost all the energy producing nutrients are finally 
oxidized to a CO2 and water. [15] Majority of living cells is normally aerobic and the 
organic fuels are completely oxidized to a CO2 and water with the help of oxygen.” 
Citric Acid Cycle” name is derived from the tricarboxylic acid, citric acid which is first 
used up at the beginning of the cycle and later regenerated to complete the cycle. In 
eukaryotes, citric acid cycle takes place inside the mitochondria, whereas in prokaryotes, 
TCA cycle takes place inside the cytoplasm.  The product of glycolysis, pyruvate is 
decarboxylated to acetyl coenzyme A in the presence of Pyruvate Dehydrogenase (PDH) 
and enters into the citric acid cycle. Pyruvate is directly converted into Oxalo Acetic 
Acid (OAA) in the presence of the enzyme, pyruvate carboxylase and ATP is consumed 
during this process.  This cycle consumes acetate obtained from fuels (carbohydrates, 
fats and proteins) and water and oxidizes it to carbon dioxide. During this process, 
NAD+ is reduced to NADH. The energy released by the oxidation of glucose to CO2 and 
water is more than energy released by the anaerobic oxidation of glucose to pyruvate.    
The end product of glycolysis, pyruvate undergoes oxidative decarboxylation 
with the help of PDH, pyruvate dehydrogenase to form acetyl-coenzyme A. [15] Acetyl-
coenzyme A is converted to citrate by donating its acetyl group to oxaloacetate. Then 
isocitrate is formed from citrate and isocitrate undergoes dehydrogenation with the loss 
of carbon dioxide to form α-Keto Glutarate (α-KG). [15] α-KG is decarboxylated to 
form succinate. Succinate is converted to fumarate by Succinate Dehydrogenase (SDH) 
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and malonate is a competitive inhibitor of SDH and results in the accumulation of 
citrate, α-KG and succinate in the mitochondria. Fumarate is converted to malate by 
Fumarate Hydratase (FH). Malate to oxaloacetate (OAA) dehydrogenation is done in the 
presence of Malate Dehydrogenase and oxalo acetate intakes the acetyl group of acetyl 
co-A to form citrate again and the cycle continues.  Pyruvate is directly converted to 
oxaloacetate (OAA) in the presence of the enzyme Pyruvate Carboxylase.  After each 
and every turn of the citric acid cycle, oxaloacetate (OAA) is regenerated and it reacts 
with Acetyl-co A to start the next turn of the cycle. During this cycle, one molecule of 
Acetyl-co A is taken in and two molecules of carbon dioxide are produced and at the end 
of the cycle, one molecule of oxaloacetate was regenerated.  One pair of hydrogen atom 
were removed from isocitrate, α-KG, succinate and malate respectively and out of this 
four pairs of hydrogen atoms, three pairs reduced three molecules of NAD+ to three 
molecules of NADH and remaining one pair of hydrogen atom reduced Flavin Adenine 
Dinucleotide (FAD) of succinate dehydrogenase to FADH2. Citric acid cycle yields one 
molecule of ATP during each turn of the cycle. The citric acid cycle figure is shown in 
figure 3.  
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2.8 Citric acid cycle and hypoxia 
Hypoxia prevents acetyl co-A from entering into the citric acid cycle and hence 
inhibits citric acid cycle and promotes glycolysis. PHD2 is the enzyme which 
hydroxylates HIF1α at the proline residue, but simultaneously PHD2 decarboxylates 
αKG to succinate. One of the intermediates of citric acid cycle, α-KG acts as a co-
substrate for PHD2 to function properly. Succinate Dehydrogenase (SDH) is the enzyme 
that converts succinate to fumarate. SDH mutation increases the concentration of 
succinate in the mitochondria, and diffuses through the inner and outer mitochondrial 
membrane into the cytoplasm.  Once inside the cytoplasm, succinate inhibits α-KG 
decarboxylation to succinate by product inhibition. This decarboxylation step is 
mandatory for PHD2 catalytic functioning and the inhibition of the same leads to PHD2 
dysfunction. This causes stabilization of HIF-1α and up regulation of hypoxia target 
genes which further inhibits citric acid cycle. People with mutations in SDH gene has 
been identified with pseudo hypoxic response nature.  Similarly, Fumarate Hydratase 
(FH) mutation results in the accumulation of fumarate inside the mitochondria, and this 
acts as a competitive inhibitor to α-KG binding site in PHD2, thereby inhibiting PHD2.  
2.9 Electron transport chain 
The four pair of electrons from the citric acid cycle is transferred through the 
ETC to the terminal electron acceptor oxygen located in the complex IV of ETC, 
reducing two molecules oxygen to four molecules of water. ETC couples the transfer of 
electrons from the electron donors NADH and FADH2 released by the citric acid cycle 
and to the terminal electron acceptor oxygen. ATP is generated by creating a 
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transmembrane proton gradient across the inner membrane of mitochondria by pumping 
protons. [15] The electron acceptor is more electronegative than the electron donor and 
the electrons passes from the donor to the acceptor until it reaches oxygen.  
There are four complexes in the ETC, namely complex I, complex II, complex III 
and complex IV. [15] Complexes I, II and IV are proton pumps and these complexes are 
connected by lipid-soluble and water -soluble electron carriers.  Complex-I accepts two 
electrons from NADH released by the citric acid cycle and passes these electrons to a 
lipid-soluble carrier ubiquinone (coenzyme Q). FAD is reduced to FADH2, during the 
conversion of succinate to fumarate. [15] Complex II accepts electrons from FADH2 and 
transfers it to ubiquinone. SDH catalyzes the oxidation of succinate to fumarate and 
during this process, ubiquinone (Q) is converted into ubiquinol (QH2).  
SDHA subunit functions as a part of citric acid cycle and converts succinate to 
fumarate and FAD to FADH2.  SDHB subunit functions as a part of respiratory chain. 
The iron clusters [2Fe-2S], [4Fe-4S], [3Fe-4S] receives the electrons from FADH2. [15] 
SDHB protein is encoded by SDHB gene, which is a tumor suppressor gene. SDHC 
cytochrome b560 subunit and SDHD cytochrome b small subunit are located at the inner 
mitochondrial membrane and functions as a part of respiratory chain. Q gets reduced to 
QH2 as a result of electron transfer from SDHB to Q (ubiquinone). 
Complex III of ETC is also known as the Q cycle.  Q cycle lists a series of 
reactions that explains how the redox reactions of coenzyme Q can pump protons across 
membrane of mitochondria to produce ATP. There are two different sites in complex III, 
the Q0 site and the Qi site. At the Q0 site, quinol is oxidized and two electrons from 
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quinone are transferred to cytochrome c. At the Qi site, quinone is reduced to quinol.  
Hence, there is a total transfer of six protons across the membrane; two protons reduce 
quinone to quinol and two quinol molecules releases two protons each.  
Complex IV is also known as cytochrome AB or cytochrome c oxidase. The 
electrons from complex III are transferred to oxygen to produce two molecules of water. 
Oxygen is the terminal electron acceptor. Simultaneously, four protons are removed 
from the mitochondria resulting in a proton gradient across the membrane.   
2.10 Electron transport chain and hypoxia 
Hypoxia inhibits ETC and results in the formation of Reactive Oxygen Species 
(ROS) from complexes I and ubisemiquinone sites of complex III. ROS accumulates in 
the cytoplasm and inhibits PHD2 by inhibiting the ability of iron (a co-factor for PHD2 
catalytic activity) to cycle between the oxidation states. This again leads to the HIF-1α 
stabilization.  HIF-1α combines with HIF-1β and HIF -1 heterodimer is formed which up 
regulates a lot of anti-apoptotic genes. During hypoxia, cells lacking mitochondria 
cannot induce HIF-1α stabilization. [17] Usually electrons from NADH and FADH2 
transfer through complexes I to IV of ETC into oxygen and reduce oxygen to water. But, 
during hypoxia, there is not much energy to transfer electrons and instead of moving 
from SDHA subunit to SDHB subunit, some electrons may directly leak into oxygen and 
generate ROS such as superoxides or peroxide anions which are dangerously reactive, 
resulting in oxidative stress.  ROS oxidizes proteins and cause DNA a mutation which is 
the main reason for premature aging and causes a lot of diseases.  High mitochondrial 
membrane potential is one of the main reasons for ROS production. So, mitochondria 
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always try to maintain the membrane potential at a narrow range to reduce ROS 
production. To lessen the aging effects of ROS cells contain many antioxidants like 
vitamin C and vitamin E.  
2.11 Oxidative phosphorylation 
The transfer of electrons between electron donor and electron acceptor through 
ETC releases a lot of energy which pumps protons (H+) from the matrix of the 
mitochondria into the inner mitochondrial membrane (IMM) space. This creates a 
transmembrane electro chemical proton gradient called ψ. This electrochemical proton 
gradient allows ATP- synthase enzyme to phosphorylate ADP to ATP and this process is 
termed as oxidative phosphorylation.  
2.12 Metabolic switch 
Figure 4 shows how hypoxia causes switch from aerobic metabolism to 
anaerobic metabolism.  Glycolysis takes place inside the cytoplasm where glucose is 
converted to pyruvate. Pyruvate is then converted to acetyl-coenzyme A with the help of 
PDH which the get into the TCA cycle inside the mitochondria. [15] Citric acid cycle 
converts acetyl-coA finally into CO2 and water and releases reduced from of Nicotine 
Amide Dinucleotide (NADH) and Flavin Adenine Dinucleotide (FADH2) which are 
electron donors. The electrons from these electron donors pass through the ETC to O2 
and water is formed as a result of the reduction of oxygen. The transmembrane gradient 
of proton produced as a result of proton pumping from the mitochondrial matrix to the 
inner mitochondrial membrane results in the phosphorylation of ATP to ADP.  
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PHD2 is the enzyme that catalyzes the non-reversible hydroxylation of the 
proline residues of HIF-1α and marks it for ubiquitination and degradation by pVHL. 
Once the PHD2 enzyme is inhibited, HIF-1α gets stabilized and enter into the nucleus 
where it heterodimerizes with Hypoxia Inducible Factor -1β and the dimeric 
transcription factor HIF-1 is formed. [2] PDH converts pyruvate to acetyl-coA, but one 
of the hypoxia target genes Pyruvate Dehydrogenase Kinase (PDK) inhibits PDH. So, 
acetyl-co A is unable to enter into the citric acid cycle and glycolysis continues 
indefinitely. Almost all the glycolytic enzymes are hypoxia target genes.  This, hypoxia 
promotes glycolysis for a rapid and easy energy harvesting.  The intermediate 
metabolites of citric acid cycle, fumarate and succinate inhibit PHD2 thereby stabilizing 
HIF-1α.  Hypoxia inhibits ETC and generates ROS which in turn inhibits PHD2.   
PHD3 hydrolyzes the proline-403/408 residues of PKM2 and this increases the 
coactivator function of PKM2. The hydrolyzed PKM2 enters into the nucleus and 
enhances the rate of HIF-1 binding to the responsive element of the target genes of 
hypoxia. PKM2 also stimulates the recruitment of p300 and CBP to the HRE of the 
target genes thereby increasing hypoxic response. Moreover, a new HRE was identified 
in the intron1 of PKM2 which shows that PKM2 itself is a hypoxia target gene. Also, 
PHD3 is also a hypoxia target gene.  Thus, PKM2 increases the transcriptional activity 
of HIF-1α. The relationship between different metabolic reactions and hypoxia is shown 
in figure 4. 
 24 
 
CoQ
CoQ
Glucose
HK
Fructose – 6 – Phosphate 
Enolase
Gluceraldehyde – 3 – Phosphate 
Dihydroxyacetone – 3 – Phosphate 
PEP
2 - Phosphoglycerate
PKM2
3 - Phosphoglycerate
1,3 - Diphosphoglycerate
Pyruvate 
PGM
PGK
GAPDH
Aldolase
Glucose – 6 – Phosphate 
PFK
GPI
Fructose 1,6 -  Diphosphate
TPI
Acetyl - CoA
PDH
OAA
Citrate
Alpha - KGSuccinyl CoASuccinate
Fumarate
Malate
II
Cytochrome C
Cytochrome C
Complex I
Complex I
Complex V
Complex V
Complex IV
Complex IV
Complex III
Complex III
O2 à H2O ADP à ATP
H
+ H
+
H
+
ROS ROS
PHD2
PHD2
O2
Fe
2+
Ascorbate
HYPOXIA
Succinate α KG
Cis - AconitateCITRIC ACID 
CYCLE
HIF - 1α
PKM2
PKM2
P300
P300
pro
pro pro
pro
OH OH
HIF - 1α
HIF - 1α
HIF - 1β
HIF - 1β
HRE
PHD2
HK
PFK
Aldolase
TPI
GAPDH
PGK
Enolase
PHD3
PKM2
PDK
EPO
VEGFA
BNIP3
NIX
NEGATIVE 
FEEDBACK
PKM2
PKM2
PHD3
PHD3
pro
pro pro
pro
OHOH
PKM2
PKM2
PHD3
PHD3
pro
pro pro
pro
OH
OH
Pyruvate 
Carboxylase 
D - Isocitrate
NUCLEUS
MITOCHONDRIA
CYTOSOL
 
Figure 4: Metabolic switch and hypoxia        
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3. P300 AND CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN-
BINDING PROTEIN (CBP) TRANSCRIPTIONAL CO-ACTIVATORS AND 
HYPOXIA 
 
3.1 Introduction 
HIF-1 heterodimer is formed once the stabilized HIF-1α gets into the nucleus and 
binds with the HIF-1β. [2] The so formed HIF-1 transcription factor binds to the 
response elements of the target genes and then recruits the transcriptional co-activating 
proteins p300 (E1A (Adenovirus early region A) binding protein p300 or EP300) and 
CBP (cyclic AMP responsive element-binding protein-binding protein). [34] P300 is a 
protein that regulates cell growth, cell division and cell differentiation and carries out 
these functions by activating transcription. P300/CBP is considered as a single entity 
because these two proteins are structurally and functionally similar and are considered as 
structural homologs and functional homologs. [35] In contrast, there are some functional 
differences between CBP and p300. For instance, the kinase cyclin E/cyclin Cdk2 
negatively regulates p300 whereas; cyclin E/cyclin Cdk2 increases the Histone Acetyl 
Transferase (HAT) activity of CBP. [36] P300 and CBP connect with transcription 
factors and these interactions are managed by their 5 protein interaction domains. [37] 
CH1, CH2 and CH3 are the 3 zinc finger domains and also has histone acetyltransferase 
(HAT) domain and a bromo domain which binds to the lysine amino acid of the histone 
that is acetylated.  The organization of p300/CBP is shown in figure 5. 
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Figure 5: Organization of p300/CBP 
 
3.2 Histone acetyl transferase  
Histone acetyl transferases (HAT) are the enzymes which can acetylate lysine 
amino acids on the histones that surround the DNA. [35] Acetylation of histone 
enhances the gene expression because, DNA is wrapped around the histone proteins and 
hence by the acetylation of histone, more binding sites are created for specific protein-
protein interaction domains such as the bromo domain which binds to the acetylated 
lysine. Both CBP and p300 function as HAT and plays a major role in cellular 
differentiation and cellular proliferation.  HATs can even acetylate the transcription 
factors. CBP/p300 acts as the transcriptional coactivators of the transcription factor 
HIF1α and enhance the gene expression of hypoxia target genes. Both CBP and p300 are 
type A HATs which are found inside the nucleus and they directly regulate gene 
expression by acetylating the lysine amino acids of the histones surrounding the DNA 
which is located within the chromatin of the nucleus. [35] One of the protein-protein 
interaction domains, the bromo domain binds to the acetylated lysine on the histones. 
[36] 
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3.3 P300/CBP as transcriptional coactivators 
P300 and CBP are the transcriptional coactivators that can increase the rate of 
gene transcription. For instance, CREB (cyclic AMP response element- binding protein) 
is one of the transcription factors. [38] It binds to a sequence of DNA within the target 
genes called CRE (cAMP response elements) and can increase or decrease the 
transcription rate of the target genes. CREB binds to CRE and CREB is phosphorylated. 
This increases the interaction of CBP and CREB and enhances the transcription of the 
target genes of CREB. [38] 
3.4 Hyper phosphorylation of P300/CBP during hypoxia 
When a cell is under hypoxic stress, the transcriptional coactivators p300 and 
CBP is hyper phosphorylated. PC12 cell lines are obtained from the pheochromocytoma 
of the medulla of the adrenal gland of rats.  Pheochromocytoma is a disease caused by 
the mutation of pVHL and the loss of VHL activity results in a drastic increase in the 
amount of HIF-1α which results in tumor.  Pheochromocytoma results in the tumor of 
the medulla of the adrenal gland. [39] The reason for hyper phosphorylation of p300 is 
due to the calcium release from IP3 (inositol 1, 4, 5-triphosphate) sensitive stores and 
this hyper phosphorylation can be inhibited by inhibiting the glucose metabolic pathway. 
[40] During glycolysis, NADH is released into the cytoplasm by the formation of 1,3-
biphosphoglycerate from glyceraldehyde 3- phosphate  with the help of glyceraldehyde 
3- phosphate dehydrogenase (G3PDH/GAPDH). [15] This NADH is transferred from 
the cytoplasm to the mitochondria by GAPDH. This transfer is activated by Ca2+. 
Glycerate phosphate shuttle transfers NADH from cytoplasm to ubiquinone (Q) and 
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complex III of the electron transport chain (ETC). [15] This NADH transfer releases a 
pool of ATP that enhances the activity of the kinases responsible for the phosphorylation 
of p300 and p300 is hyper phosphorylated. [40]  
3.5 P300/CBP and tumor suppression 
P300 and CBP are involved in several tumor suppressor pathways and is 
demonstrated by its interaction with the tumor suppressor gene p53. [41] P53 interacts 
with the carboxyl terminal region of CBP/p300 and thus the rate of transcription of the 
p53 response genes MDM-2, p21 were increased. [42] Adenovirus E1-A interacts with 
p300/CBP at the zinc finger region and block its activity.  P300/CBP can regulate p53 
degradation. During DNA damage, p53 activates its target gene MDM-2, but MDM-2 
inhibits p53 and this is a negative feedback. E1-A does not allow p53 to induce MDM-2 
and hence p53 is stabilized by suppressing the feedback loop. MDM2 and p53 binds to 
the first zinc finger domain of p300. MDM-2 can inhibit p53 by competing for 
p300/CBP binding site. For instance, MDM-2 competes with p73, which is a homolog of 
p53 for binding with the first zinc finger domain of p300 and prevent its interaction with 
p300. [43]  
The knowledge that p300/CBP can act as tumor suppressors are further 
strengthened by the interaction of p300/CBP with the tumor suppressor gene BRCA1 
(breast cancer type 1), by acting as a transcriptional regulator of BRCA1. [44] Moreover, 
CBP negatively regulates Wnt pathway in drosophila. If the Wnt pathway is up regulated 
or activated, then the gene cyclin D1 and the proto oncogene c-myc will be induced and 
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this can cause tumor. [45] The negative regulation of wnt pathway by CBP is shown in 
figure 6. 
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Figure 6: Negative regulation of wnt pathway by CBP 
 
3.6 P300/CBP and E1A 
CBP/p300 interacts with a lot of viral onco- proteins such as v-myb. C-myb is a 
proto oncogene and v-myb is an oncogene which is carried by the avian myeloblastosis 
virus (AMV). C-myb binds to the CREB binding domain (KIX domain) of CBP and thus 
enhances its transcription.  But, at the same time, there are other viral onco-proteins such 
as adenovirus E1-A, human papilloma virus E6 etc. which can block the complete 
functioning of CBP/p300. These viral onco-proteins do not bind to the DNA but, the 
amino terminus of E1A bind to CH3 of CBP/p300. So, E1A functions by blocking the 
interaction of p300/CBP with these positive effectors of these coactivators.  But, the 
carboxyl terminus (C-terminus) of E1-A inhibits the histone acetyl transferase activity of 
CBP/p300 directly, even without having to displace the positive effectors. But, a very 
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high level of E1-A is required to inhibit the HAT activity of CBP/p300 directly. [44] The 
interaction of E1-A with CBP/p300 is shown in figure 7. 
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Figure 7: E1A and CBP/p300 
 
The E6 protein of human papilloma virus (HPV) degrades the tumor suppressor 
gene p53, by recruiting p53 into a complex that contains the ubiquitin ligase E6AP. E6 
proteins from the invasive cervical carcinoma bind to the third zinc finger domain, 
displacing p53 from its transcriptional coactivator because p53 also binds to the third 
zinc finger domain (CH3). This results in p53 degradation by ubiquitination. [46] 
Both CBP and p300 are regulated by phosphorylation. Cyclin Cdc2/Cyclin Cdk2 
are the kinases that phosphorylate CBP/p300 and enhances their transcriptional 
coactivator functioning. But, adenovirus E1A has the ability to block the 
phosphorylation of CBP/p300 by these kinases.  These coactivators are also negatively 
regulated by the kinase cyclin E/cyclin Cdk2. But, the cyclin-dependent kinase inhibitor, 
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p21 blocks this negative regulation of p300 by cyclin E/cyclin Cdk2. P21 enhances the 
efficiency of p300 as a transcriptional coactivator. Thus, p21 participates in a positive 
feedback loop as follows:  p53 which depends upon CBP/p300 induces p21 which 
removes the block on CBP/p300 by the kinase cyclin E/cyclin Cdk2 and enhances the 
transcriptional coactivator function of CBP/p300. [47] 
3.7 P300/CBP mutations 
The mutations in CBP/p300 results in a variety of developmental disorders like 
RTS (Rubinstein-Taybi Syndrome).  People with mutations in CBP/p300 possess an 
increased risk of developing cancerous and non-cancerous tumors, leukemia and 
lymphoma.  Most of these tumors develop during childhood. RTS occurs because of the 
mutation that happens in only one copy of CBP which reduces the production of CREB 
binding protein by half. This protein is very much essential for growth and development 
before and after birth. RTS is a developmental disorder and is characterized by mental 
retardation, broad thumb, unusual facial appearance and broad and big toes. One out of 
every 1, 00,000 newborns are affected by RTS due to deletions, point mutations, or 
translocations in the CBP gene. [48] The thyroid hormone receptors depend on the 
transcriptional coactivators CBP/p300 for their function. Even though RTS patients have 
mutant CBP, the thyroid functions of these patients appear to be normal.  This is 
probably because, the affinity of CBP towards the activated thyroid hormone receptors 
are so high that a reduction in the amount of CBP cannot disrupt the interaction between 
CBP and thyroid hormone receptors or may be some other hormone receptor 
coactivators are masking the consequences of CBP deficiency. [44]   
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3.8 P300/CBP associated factor  
P/CAF or PCAF (CBP/p300 associated factor) is a transcriptional coactivator 
associated with the tumor suppressor gene p53. [49] The protein encoded by PCAF and 
adenovirus E1A binds to the third zinc finger domain (CH3) of CBP/p300 and hence 
both compete for the same binding site within CBP/p300.  PCAF inhibits the cell cycle 
progression and adenovirus E1A functions by blocking the interaction between 
CBP/p300 and PCAF. [35]   
3.9 Interaction with transcription factors 
Both CBP and p300 play a major role in regulating transcription by its interaction 
with hundreds of transcription factors. CBP/p300 is called transcription coactivators 
because they bind to the transcription factor and enhances the rate of transcription by 
positioning histone acetyl transferase (HATs) near precise nucleosomes. [35] There are  
three zinc finger domains for CBP/p300, CH1, CH2 and CH3 and they are the binding 
site for numerous transcription factors which indeed makes CBP/p300 an important 
regulator of transcription mechanism. [40] P300 contains a Protein Kinase A (PKA) site 
near to the third zinc finger domain (CH3) and new studies suggest that phosphorylation 
by PKA regulates p300/CBP. [36] 
HAT activity links chromatin remodeling and transcriptional activity. [40] HAT 
activity is not required for the transcription of naked DNA templates, but histone acetyl 
transferase activity is required for releasing the chromatin structure of the histones 
surrounding the DNA. This weakens the DNA –histone bond and hence protein 
translation increases because more binding sites are available for the transcription factors 
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to associate with the DNA. [36] P300/CBP contributes to transcriptional synergy by 
interacting with several transcription factors simultaneously. Even though they bind to 
hundreds of transcription factors, the concentration of CBP/p300 in the cells is very 
limited and hence a small decrease in the amount of these coactivators is very much 
damaging to the cell.  
Both p300 and CBP are targeted by the adenovirus E1A. The transcription factor 
HIF-1α binds to the first zinc finger domain (CH1) of p300. [50] P300 upregulates the 
EPO gene in response to hypoxia. When a cell was induced with hypoxic conditions, a 
DNA binding complex was formed which contained the transcription factor HIF1α as 
well as the transcriptional co-activators p300 and CBP. [50] When enough energy is not 
available, cAMP (the energy sensor), is upregulated and then the transcription factor 
CREB bound to the CRE recruits CBP which functions as a transcriptional coactivator  
and binds to the transcription factor CREB and upregulates the cAMP responsive genes. 
The adenovirus ze1A can transform normal cells to malignant cells only when it is 
associated with p300/CBP. So, p300/CBP plays a major role in suppressing neoplastic 
transformation. [50]   
E1A targets CBP/p300 and inhibits hypoxic induction of the target genes EPO 
and VEGF.  P300/CBP is involved in the upregulation of a variety of hypoxia target 
genes.  [50] E1A has the ability to bind to a number of transcription factors and thus act 
as scaffolds binding to different transcription factors directly and integrating genetic 
information from various transcription factors. Thus, they contribute to transcriptional 
synergy. [51] So, even though p300/CBP is known for its tumor suppressor 
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characteristics, it can also support tumor progression by associating with oncoproteins 
such as E1A. Hence, p300/CBP –HIF complex can be a target for cancer therapy. [50]      
3.10 P300/CBP and p35srj protein 
p35srj protein, a 35KDa cellular protein was identified, cloned and named as 
p35srj for its serine – glycine rich junction by Bhattacharya in the year 1999 and is a 
novel protein. The p35srj protein which binds to CH1 (the same binding site for HIF1α), 
inhibits the HIF1α-CBP/p300 association.  
But, p35srj protein itself is a hypoxia inducible protein. So, this is a negative 
feedback regulation for hypoxia. [52] The p35srj protein is very unstable and is 
completely bound to p300/CBP through the carboxy terminus. P35srj blocks the 
association of HIF1α –CTAD (C terminal activation domain) with p300/CBP and that is 
how it inhibits HIF1 activity. [40] Thus, p35srj regulated HIF1 transcription in a 
negative feedback mechanism which is shown in the figure 8.     
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Figure 8: Negative feedback regulation of HIF1 by the protein p35srj 
 
 36 
 
3.11 Hypoxia induces hyper phosphorylation of P300/CBP 
P300 and CBP both being phospho proteins, hyper phosphorylation of p300/CBP 
is caused due to the release of Ca2+ ions from the IP3 sensitive stores. [40] In the paper 
Adriana et al. the inhibitors of IP3 receptors 2APB and Xestospongin C were used in the 
cells exposed to 1% hypoxia for 3 hours and that inhibited the hyper phosphorylation of 
p300/CBP. [40] Specific glucose metabolic pathways need to be activated for the hyper 
phosphorylation of p300. Calcium ions (Ca2+) activate the enzyme G3PDH. [40] NADH 
passes through the mitochondrial membrane with the help of glycerol phosphate shuttle. 
[40] G3PDH reduces dihydroxyacetone to glycerol- 3- phosphate inside the cytoplasm 
with the help of NADH and oxidizes glycerol-3-phosphate back to dihydroxyacetone 
inside the mitochondria with the help of  FAD and during this process, FADH2 is 
generated which is produce reducing equivalents to ubiquinone (Q) and to complex III of  
the mitochondria. [40] Glycolysis is inhibited by 2-deoxyglucose, which prevents the 
hyper phosphorylation of p300 and iodoacetate an inhibitor of GAPDH prevented the 
accumulation of HIF1α during hypoxia. [40] Moreover, the cells treated with substrates 
hydroxybutarate, pyruvate and α-keto Glutarate (α-KG) which activates the Krebs’s 
cycle and generate NADH at complex I was not able to induce hyperphosphorylation of 
p300 in hypoxia induced cells which indicates that, for the hyperphosphorylation of 
p300 to occur, glycolysis is very much essential. [40] Palmitoyl coenzyme A, an 
inhibitor of G3PDH and DPI (diphenyliodonium) which is an inhibitor of FADH2 
decreased the p300 hyperphosphorylation. [40] The pathways responsible for the hyper 
phosphorylation of p300 during hypoxia is shown in the figure 9.  
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Figure 9: Pathways responsible for the hyper phosphorylation of p300 during hypoxia 
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4. TRANSLATIONAL CONTROL OF GENE EXPRESION DURING HYPOXIA 
 
4.1 Introduction 
Translation is the process by which messenger RNA (mRNA) is decoded by the 
ribosome complex to produce amino acid chain which folds to produce proteins. [53] 
During hypoxia, the gene expression of the target genes is controlled by regulating the 
process of translation and this is done by controlling the initiation steps of mRNA 
translation. [54] This is also the strategy adapted by solid tumors for growth and 
development, as it faces severe oxygen crisis since, the normal supply of oxygen falls 
short to satisfy the increasing demand of oxygen. [2] The phenomenon of protein 
synthesis requires a lot of energy. In order to save energy, protein synthesis is 
suppressed during hypoxia by regulating the initiation steps of mRNA translation by two 
different pathways, either by the phosphorylating eIF2 which is the eukaryotic initiation 
factor 2α or by inhibiting eIF4F, which is another eukaryotic initiation factor. [54] 
During hypoxia, even though there is a decrease in translation, there is not much 
translation inhibition at the individual gene level because of the presence of 3’ and 5’ 
untranslated regions of messenger RNA. [54] 
4.2 PI3K/AKT/mTOR pathway 
The growth factors like IGF1 (Insulin Growth Factor 1), IGF2 (Insulin Growth 
Factor 2) etc. sustains oxygen homeostasis in growing cells by activating the signaling 
pathways that includes phosphoinositide 3-kinase (PI3K), Protein Kinase B (PKB aka 
AKT) and mTOR (mammalian Target of Rapamycin). [2] EIF-4E (eukaryotic translation 
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initiation factor -4E) is increased due to this activity, which increases the translation of 
HIF-1α messenger RNA. [2] MTOR (Mammalian Target of Rapamycin) is a protein 
encoded by FRAP1 (FK506 binding protein 12-Rapamycin associated Protein 1) gene in 
humans. [55] Rapamycin is a product of bacteria which can inhibit mTOR activity. 
MTOR has FK506 binding protein 12 – Rapamycin (FBR) binding domain. [56] Once 
this rapamycin binds to mTOR, it impedes the mTOR activity.  The main function of 
mTOR is to collect the inputs from the growth factor pathways. The activities of mTOR 
include regulation of synthesis of proteins, transcription of various genes, cell 
movement, growth, proliferation and survival of cells. [56] PI3K (phosphoinositide -3 
kinase) are a family of intracellular enzymes which can phosphorylate 
phosphatidylinositol at its 3 position hydroxyl group of inositol ring.  The main 
functions of PI3K are cell differentiation, cell motility, cellular growth, survival, 
proliferation and trafficking. [57] AKT is a protein kinase which is threonine/serine 
specific protein kinase that can activate mTOR. [58] AKT is involved in several 
important cellular processes such as metabolism of glucose, migration and proliferation 
of cells etc. and is able to induce protein synthesis pathways necessary for growth and 
development. [58] AKT binds to PIP3 (Phosphatidylinositol (3, 4, 5)-triphosphate) or 
PIP2 (Phosphatidylinositol (4, 5)-biphosphate) with high affinity. Once PI3K is activated 
by the signals from the upstream growth factors like IGF1, IGF2 etc. PI3K 
phosphorylates PIP2 to PIP3. Then, AKT binds to PIP3 and AKT is phosphorylated by its 
kinases mTORC2 (Mammalian Target of Rapamycin Complex 2) and PDPK1 
(phosphoinositide dependent kinase 1) Phosphorylation of mTORC2 results in the 
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phosphorylation of AKT by PDPK1. Once AKT is phosphorylated, it results in mTOR 
activation by its kinase activity. [59] PI3K/AKT/mTOR pathway is very important in the 
context of cancer because, they integrate signals from the upstream growth factors like 
IGF1, IGF2 etc. and reduces apoptosis and increases proliferation which contributes to 
cancer. PI3K activation leads to AKT activation which finally leads to mTOR activation. 
[60] PI3K/AKT/mTOR pathway is over reactive in cancer cells due to the faults or 
deficiencies in the tumor suppressor gene, Phosphatase and Tensin homolog (PTEN). 
The action of the phosphatase protein product of PTEN is responsible for its tumor 
suppression characteristic. It inhibits PI3K/AKT/mTOR pathway by converting PIP3 to 
PIP2. This tumor suppressor gene is involved in cell cycle regulation, and prevention of 
rapid cell division. [59] PTEN is one of the most mutated or lost tumor suppressor gene 
in almost all types of human cancers and approximately 70% of men with prostate 
cancer have already lost one copy of tumor suppressor PTEN gene by the time this 
disease is diagnosed. [61] Defect in the tumor suppressor genes PTEN and p53 results in 
a decrease in the neuronal energy production which leads to abnormal energy level 
production in hippocampus as well as cerebellum of the brain leading to autism. [62] To 
sum up, PI3K/AKT/mTOR pathway is inhibited by PTEN that works antagonistically to 
PI3K. The drastic reduction in AKT activation is because of the membrane localization 
factor from AKT. [61] 
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4.3 Unfolded protein response  
Hypoxia results in suppression of protein synthesis by regulating the initial steps 
of mRNA translation and is linked to the activation of Unfolded Protein (UPR) due to 
Endoplasmic Reticulum stress.  In this case, the process of translation is inhibited 
because the Eukaryotic Initiation Factor (eIF2α) is phosphorylated in a PERK dependent 
manner. [54] The stress in the organelle endoplasmic reticulum results in a cellular state 
response called Unfolded Protein Response (UPR).  Due to this stress many proteins that 
are not folded properly accumulates inside the endoplasmic reticulum lumen. In this 
scenario, the UPR has two aims. First, it will stop the protein synthesis for some time 
and activate those signaling pathways that could increase the synthesis of molecular 
chaperones that are involved in proper folding of the proteins.  This has to be done 
within a certain time limit. If they are unable to correct the misfolding with a certain 
time frame, unfolded protein response results in apoptosis of the cells facing ER stress. 
[63] EIF2α is the α subunit of eIF2 dimer and is involved in the initiation of translation. 
Ribosomes are the basic building blocks of proteins and they build proteins based on the 
messenger RNA information. EIF2 is a eukaryotic initiation factor that facilitates the 
binding of transfer RNA (tRNA) to ribosomes. A ternary complex (TC) is formed by the 
combination of eIF2, GTP (Guanosine Tri Phosphate) and the initiator methionine-tRNA 
(met-tRNA).Methionine is an amino acid that is coded by the initiation factor AUG 
codon which is the most common eukaryotic start codon. 
The GDP has to be exchanged with another GTP and only the GTP-bound eIF2 
can participate in another translation initiation. [64] After the formation of the ternary 
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complex, 43S Pre Initiation Complex (PIC) is formed once it binds with the small 
ribosomal subunit. Then, eIF4S unwinds the mRNA, to which the 43SPIC will later 
bind.  Then the initiation factor eIF4S and 43S PIC forms the complex 48S on the 
mRNA and runs along the mRNA in search of the start codon AUG. [64] Now, once the 
start codon AUG is located, then the met-tRNA base pairs with the AUG codon and a 
protein that activates the GTP-ase, eIF5 recruits to the 48S complex and GTP is 
hydrolyzed to GDP by eIF2. [65] This results in the release of eIF2-GDP from the 48S 
complex and recruits the large ribosomal subunit, and forms the 80S initiation complex 
and finally the process of translation begins. [64] The Guanine Nucleotide Exchange 
Factor, eIf2B helps eIF2 to exchange its GDP for a GTP and a new round of translation 
initiation begins. [65]  
The translation inhibition during the initial phase of mRNA translation is 
achieved by the phosphorylation of eIF2α. [54] The kinases act as a result of 
Endoplasmic Reticulum stress (PERK). The affinity of eIf2α for eIF2B increases due to 
the phosphorylation of eIF2α. But, eIF2B exchanges GDP (Guanosine Di Phosphate) to 
GTP (Guanosine Tri Phosphate) only with the unphosphorylated eIF2. EIF2B is 
inhibited by phosphorylated eIF2. The cellular concentration of eIF2B is very low when 
compared to the cellular concentration of eIF2. [66] 
PERK or Eukaryotic Translation Initiation Factor2- Alpha Kinase -3 (EIF2AK3) 
is related to the Unfolded Protein Response (UPR). If there is an increase in the amount 
of proteins not folded properly  in the endoplasmic reticulum lumen, BiP/GRP78 
chaperones bind to these proteins and so BiP/GRP78 dissociates from their from their 
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corresponding receptors to bind to these proteins. [67] PERK oligomerizes with BiP in 
the ER stressed cells. [67] The activated PERK attenuates transcription by 
phosphorylating the α subunit of translation machinery, eIF2. PERK also can induce 
apoptosis by activating the pro apoptotic protein, CHOP (CCAA1/ enhancer binding 
protein homologous protein). [67] CHOP down regulates anti apoptotic protein BCL2. 
[68]  
4.4 Regulation of translation during hypoxia through eIF2 
Both severe and moderate hypoxia can cause the phosphorylation of eIF2α. [54] 
The difference is that during severe hypoxia, the phosphorylation of eIF2 occurs very 
rapidly within just 30 minutes when compared to the eIF2α phosphorylation by moderate 
hypoxia. [69] Moreover, this raid phosphorylation process is totally reversible due to 
ATP depletion during hypoxia.  Due to the negative feedback loop in the hypoxic stress 
response pathway, even though the rapid phosphorylation occurs within half an hour, 
within a time span of about 4-8 hours, it partially recovers. By analyzing the levels of 
ribosomal association with mRNA, it is validated experimentally in ref. 54 that hypoxia 
reduces the number of ribosomes required per translation and shift to lower ribosomal 
density. [54] Thus, the translation inhibition by the phosphorylation of eIF2α impairs the 
ternary complex (TC) and decreases the ribosomal recruitment to transcripts of 
messenger RNA. [54] The pictorial representation of the regulation of the inhibition of 
translation is shown in the figure 10.  
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Figure 10: Translation inhibition by phosphorylation of eIF2α 
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5. RESULTS AND CONCLUSIONS 
 
5.1 Introduction 
 In Biology, almost all the knowledge and information is available as signaling 
pathways. They are unable to represent the multivariate interaction between the genes, 
even though they can give a pictorial representation of the univariate interactions. [70] 
There are also possibilities that two or more pathways can share the same genes or the 
same node. Thus, a biological pathway gives a clear cut idea of the relationship between 
different genes in that pathway, but fails to provide the information about how these 
genes interact globally when they are present in different pathways. [71] The main aim 
of this work is to generate a Boolean network whose state transitions realize the hypoxic 
stress response pathway. The resulting Boolean network obtained shows dynamic 
behavior which is consistent with the experimental results and observations from the 
already published literatures.  
 By incorporating the expert knowledge obtained from the biological pathways, 
the cardinality of the search space of the network can be reduced. The main drawback of 
the pathway knowledge is that it provides only partial information and that too restricted 
to a specific context [71]. By mathematically modeling the multivariate interaction 
between the genes in a pathway, these networks can be used to differentiate between 
normal cell behavior and diseased cell behavior [70]. By working with the genetic 
regulatory networks instead of the biological pathways, the holistic behavior of the genes 
can be captured and the appropriate therapeutic interventions can be developed. The 
 46 
 
main aim of the biological pathways is to demonstrate the complex interactions taking 
place inside a cell when a stimulus or stress is applied. [71] 
5.2 Stress response pathways 
 The main aim of adaptive stress response pathways is to activate the 
transcription of cytoprotective genes [34]. Metazoans respond to the stress via growth 
factors to promote the growth of the organisms. [34] But, if a stress is applied to a cell 
exogenously such as xenobiotic, radiation, heat etc. these cells respond via several 
highly conserved adaptive stress response pathways that will try to attenuate the 
consequences of these stress and re-establish the homeostasis. [34]  
 The rapid response of these stress response pathways can be attributed to the 
architecture of the stress response pathways. [70]. Basic components of this architecture 
include a transcription factor, a sensor and a transducer. A schematic diagram of the 
architecture of the stress response pathways is shown in figure 11. 
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Figure 11: Architecture of the stress response pathways 
 
 A transcription factor is a protein which binds to the DNA through the 
response elements within its promoter region and thus activates or upregulates the 
expression of the target genes. [34] During the absence of stress, the transcription factor 
is prevented from entering into the nucleus with the help of a protein known as a sensor. 
It interacts with the transcription factor in such a way that the transcription factor is 
sequestered in the cytoplasm. [34] When a cell is faced by a stress, an enzymatic protein, 
transducer, transfers a cue from a pathway which lies upstream of the 
sensor/transcription factor complex. [34] The transducer either modifies the transcription 
factor or modifies the sensor which destabilizes the sensor/transcription factor complex. 
The activated transcription factor then enters to the nucleus and upregulates the target 
genes. [72]     
5.3 Network modeling  
 Given two genes/proteins A & B and their binary values a, b є {0, 1}, a 
pathway segment,  means that, if gene A assumes the value a then, gene B 
transitions to the value b in no more than t subsequent time steps. [71] Similarly, a 
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pathway is defined as a sequence of pathway segments of the form, . [71] 
A Boolean network (BN), γ = (V, F), on n genes is defined by a set of nodes/genes 
V={x1, …, xn }, xi є {0,1}, i =1,…., n, and a list F= (f1 ,….., fn), of Boolean functions, fi : 
{0, 1}n à{0, 1}, i=1, …., n . [73] The gene expression of each gene is quantized to two 
levels, 0 and 1. The node xi represents the gene expression of the gene i, where xi= 0 
means that, gene i is off and xi = 1, means that gene i is ON. [70] The predictor function 
fi updates the states of all the genes in γ at every time step. The network state also called 
the Gene activity Profile (GAP) of the network at time t is given by, x (t) = (x1(t), 
x2(t),….., xn (t)). [71] The prior biological knowledge of the hypoxia stress response 
pathway is used to model the Boolean networks of hypoxia stress response pathway. In 
order to get an update equation, for each and every gene in the Boolean network 
obtained, the Karnaugh map reduction technique is applied to it. [71] The hypoxia stress 
response pathway is shown in figure 12.  
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Figure 12: Hypoxia stress response pathway 
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 The pathway segments from the pathways in the above figure are given below: 
       (5.1)    
        (5.2)  
        (5.3) 
        (5.4) 
        (5.5) 
        (5.6) 
        (5.7) 
      (5.8) 
        (5.9) 
        (5.10) 
From the above described pathway segments and applying the techniques of K 
map reduction explained in [71], the update equation of each and every gene is obtained. 
The state space is defined as [PHD2 HIF HRE ROS PDK PYRUVATE]. A set of 
possible Boolean networks were obtained, out of which the one that matched most to the 
prior literature knowledge were chosen. The update equations are given below: 
O2next = Hypoxia       (5.11) 
PHD2= (PYRUVATE + ROS)*(O2+ HRE)    (5.12) 
HIFnext = PHD2        (5.13) 
HREnext = HIF        (5.14) 
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ROSnext = HRE        (5.15) 
PDKnext = HRE        (5.16) 
PYRUVATEnext = PDK      (5.17) 
 This Boolean network will have two different contexts based on the value of 
the hypoxic stress, i.e., when Hypoxia =0 and when Hypoxia =1. Figure 13 shows the 
diagram of state transition when hypoxia=0. In this diagrams showing the state transition 
the order of the genes in the binary state representation are as such: [PHD2 HIF HRE 
ROS PDK PYRUVATE]. For the ease of demonstration, the decimal equivalents are 
used to represent their binary states. For example, the decimal equivalent 31 is used to 
represent its binary state (011111). The attractors give rise to the steady state properties 
of the network obtained.  
 There are two singleton attractors 32(100000) and 31(011111) in the diagram 
showing the state transition during normoxia. This is shown in figure 3. Actually, the 
singleton attractor, 31(011111) is present in both cases of Hypoxia=0 and Hypoxia =1, 
which is not biologically possible.  When hypoxic stress is not applied, that is during 
normoxia, PHD2 is active and HIF1α is hydroxylated by PHD2, which results in the 
degradation of HIF1 and the genes/proteins ROS, PDK and Pyruvate are OFF. Thus, 
when hypoxia is 0, the presence of the singleton attractor 31(011111) does not make any 
sense because PHD2 will be ON and the rest of the genes will be OFF in this case. From 
the previous biological knowledge from ref.2, it is clear that during the absence of 
hypoxic stress all other genes except PHD2 is inactive. Thus, the presence of singleton 
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attractor 32(100000) when Hypoxia=0 is consistent with the biological literature. The 
state transition diagram when hypoxia = 0 is shown in figure 13. 
 
 
Figure 13: State transition diagram when hypoxia = 0 
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 Next, when Hypoxia=1, the state transition diagram in figure 14 is obtained 
and in this case, the state space is partitioned. There are two steady state cyclic attractors 
involving cyclic variation in the experimental patterns of all the 6 genes/proteins. The 
final attractor cycle will depend on the starting state, one of them cycling through the 
states 47 (101111)à 3 (000011)à17 (010001)à28 (011100)à62 (111110)à 
47(101111) and the other attractor cycle cycling through the states, 63 (111111)à15 
(001111)à19 (010011)à29 (011101)à30 (011110)à63 (111111). So, the time 
domain response during hypoxia exhibit cyclic oscillations. Hence, during normoxia, the 
system rests in one state only, whereas during hypoxia, the genes or nodes oscillate in a 
cyclic manner. The state transition diagram when hypoxia =1 is shown in figure 14. 
 
 
Figure 14: State transition diagram when hypoxia = 1 
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5.4 Time domain simulation results  
 To understand the functionality of the Boolean network described by equations 
from (5.11) to (5.17), an external stress input signal was given for a duration of 100 time 
steps to simulate the Boolean network obtained using MATLAB. The simulated time 
course behavior of the expression pattern of the nodes, PHD2, HIF, HRE, ROS, PDK, 
and Pyruvate are shown in figure 15 below for the case when hypoxia = 0. 
 
 
Figure 15: Time response behavior when hypoxia = 0 
 
 When O2 = 1, it implies that hypoxic stress = 0 and when O2 = 0, it implies that 
hypoxic stress = 1. From the simulations obtained in figure 15, it is clear that PHD2 is 
activated and the rest of the genes are deactivated when the cell is not subjected to 
hypoxic stress.  From the time response behavior in figure 15 it is clear that there is an 
out of phase relationship between PHD2 and the rest of the genes. The time response 
behavior of the system when hypoxia =1 is shown in figure 16. 
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Figure 16: Time response behavior of the system when hypoxia = 1 
 
5.5 Literature validation 
 
 Reference 74 shows that the optimal HIF1α transcriptional activity requires 
sequential inhibition of PHD2. [74] Here, they used the pharmacological inhibitor JNJ-
42041935which  inhibits the hydroxylation of HIF1α by PHD2, via displacing the 
endogenous 2-oxalogluatarte co-substrate required for the proper functioning of PHD2. 
[75] The figure 2 of that paper shows the densitometric analysis of the western blot 
which demonstrates the stabilization of HIF1α at 3% of oxygen and more amount of 
HIF1α stabilization at 1% of oxygen in Human Embryonic Kidney cells transfected with 
pGluc-HRE At 21% of oxygen concentration that is during normoxia, there was no 
HIF1α stabilization (figure 2(C)), which shows that HIF1α stabilizes during low oxygen 
tension. Figures 3(B) to 3(D) and 3(G) and 3(H) experimentally validate the HIF1α 
stabilization when PHD/FIH is inhibited. 
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 Reference 76 presents an experimental based computational method that shows 
the in phase relationship between ROS and HIF1α. Therapeutic agents target five 
compounds that is involved in HIF1α hydroxylation, i.e. iron (Fe), ascorbate (Asc), 
hydrogen peroxide (H2O2) 2-oxaloglutarate (2-OG) and succinate. H2O2 oxidizes ferrous 
iron (Fe2+) to ferric iron (Fe3+) and prevents the binding of ferrous iron to PHD2. [76] 
Thus, the PHD2 action is inhibited and HIF1α is stabilized. Moreover, H2O2 recruits 
ascorbate as a free radical scavenger not allowing to reduce ferric iron to ferrous iron 
and also prevents ascorbate from binding to PHD2 which inhibits the PHD2 action. [76] 
Free radicals and mitochondrial dysfunction alter the concentration of 2-OG and 
succinate which is involved in HIF1α hydroxylation. ROS affects HIF hydroxylation by 
changing H2O2, Fe
2+, ascorbate, 2-OG and succinate. [76] The figure 2(A) in that paper 
shows the effect of ROS on HIF1α by changing the ascorbate and Fe2+ levels. In the 
normal conditions, when Fe2+ and ascorbate were upregulated, HIF1α reached its peak 
value within an hour. Next, when ROS production was increased by 10 fold by 
decreasing Fe2+ and ascorbate concentrations, it led to 5 fold increase in the maximum 
HIF1α expression. This clearly explains that ROS and HIF1α are in phase. Figure 2(B) 
in this paper shows the experimental result that a 10 fold decrease in Fe2+ and 2-OG 
concentration results in increased ROS and HIF1 activity, whereas a 10 fold increase in 
Fe2+ and 2-OG concentration results in decreased HIF1 concentration. [76] Thus, this 
paper experimentally validates the in phase relationship between HIF1α and ROS. 
 Reference 17 experimentally validates that hypoxia activates the transcription 
of several hypoxia target genes by increasing ROS concentration. [17] In this paper, they 
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selected ρ0 cells by exposing Hep3B cell culture to mitochondrial inhibitors rotenone 
and antimycin A. [17] The measurement of ROS was done using 2’, 7’-dichloroflurescin 
(DCFH) diacetate. ROS oxidizes DCFH to 2’, 7’-dichloroflurescin DCF).  Experimental 
results in figure 1(A) of that paper shows that the cellular oxygen uptake by ρ0 cells was 
approximately only 10% of the total cellular uptake of oxygen by wild type Hep3B cells 
which indicates that almost all the oxygen is used up in the mitochondria. [17] Figure 
1(C) of that paper shows that there is no EPO secretion in ρ0 cells during hypoxia (1.5% 
of oxygen), which means that the organelle mitochondria is very much essential for the 
induction of hypoxia target genes, whereas in wild type Hep3B cells, there is a high 
amount of EPO secretion during hypoxia (1.5% of oxygen). 
 When ρ0-Hep3B cells were exposed to hypoxia, it did not display any HIF-1 
DNA binding activity [17]. This paper experimentally validates that mitochondria is 
very much essential for transcriptional activity of hypoxia. DCFH diacetate was used to 
assess the ROS production in the Hep3B wild type cells. H2O2 oxidizes DCFH to DCF. 
[17] Figure 2(A) of that paper shows the fluorescence of DCF at various levels of 
oxygen. During normoxia, (8% of oxygen), there was no DCF fluorescence (ROS 
generation) at all. To strengthen the fact that the complex III of mitochondria is the 
major site of ROS production, inhibitor of complex I of mitochondria, rotenone and 
inhibitor of complex III of mitochondria, myxothiazol were administered during 
hypoxia. [17] Both these inhibitors resulted in a decrease in DCF fluorescence (ROS 
generation) during hypoxia indicating that complex III is the major site of ROS 
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production during hypoxia. Figures 3(B) to 3(C) and 3(D) of that paper shows the same 
results.  
 Reference 77 experimentally validated that the glycolytic enzymes which are 
the hypoxia target genes are very much important for the metabolic adaptation to 
hypoxia by increasing the conversion of glucose to pyruvate and finally the 
accumulation of lactate. [77] They observed that, HIF1α null mouse embryo fibroblasts 
(MEFs) failed to upregulate PDK1. This shows that PDK1 is a direct hypoxia target gene 
i.e. an in phase relationship between HRE and PDK1. The immunobolt assay in figure 1 
in that paper shows the increased expression of PDK1 in hypoxic cells by HIF1. [77] 
Moreover, HIF1α null MEFs did not express PDK1, whereas the wild type MEFs 
showed a drastic increase in PDK1 gene expression clearly depicted in figure 1(C) of 
that paper.  
5.6 Conclusion and future work 
 Thus, the Boolean network was developed that could generate trajectories 
consistent with the hypoxia stress response pathway. The resulting network exhibited 
dynamic behavior consistent with the published literature where ever applicable. 
The literature validations considered only 2 genes/proteins at a time. They did not 
experimentally validate the simultaneous expression of these 6 genes i.e, PHD2, HIF, 
HRE, ROS, PDK and Pyruvate during hypoxia. There is need for more experiments 
validating the multivariate relationship between these genes rather than focusing on the 
univariate relationships. 
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 Since hypoxia is related to almost all the pathological conditions, especially 
cancer, stroke, atherosclerosis and asthma, proper drug interventions can be hopefully 
developed by targeting to control the simultaneous oscillations of these six genes during 
hypoxia. 
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